

## **PERCHERON APPOINTS DEBORAH AMBROSINI AS CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY**

**Melbourne, Australia – 17 June 2024:** Percheron Therapeutics Limited, an international biotechnology company focused on the development of novel therapies for rare diseases, is pleased to announce, in accordance with Listing Rule 3.16.1, the appointment of Deborah Ambrosini as Chief Financial Officer and Company Secretary, with immediate effect.

Ms Ambrosini will be responsible for communication with ASX in relation to Listing Rules matters under Listing Rule 12.6.

“We are delighted to welcome Deborah to the Percheron team,” commented Percheron CEO, Dr James Garner. “As we engage more actively with potential partners, and as we begin to present the company to a much broader range of potential investors, it is timely to bring a CFO with Deborah’s formidable experience on board. She brings a track record of success, a rich professional network, an impressive work ethic, and a wealth of technical experience to the company, and we look forward to working with her as we continue to implement the strategy the Board has laid out.”

Ms Ambrosini is a highly experienced corporate executive with more than twenty years of experience as a Chief Financial Officer in both private and ASX-listed companies. She is a Chartered Accountant by training and began her career with PricewaterhouseCoopers. Since then, she has helped to grow companies across a range of industries. In addition to her accounting qualifications, she holds a Certificate in Governance Practice from the Governance Institute of Australia. Ms Ambrosini is well versed in regulatory compliance, contract negotiation, statutory compliance, financial reporting, financial analysis and forecasting, and both debt and equity capital raising. Her prior experience in the healthcare sector includes Cortical Dynamics Limited, Acrux Limited, and Cann Group Limited.

“I am excited to join Percheron at this critical time,” commented Ms Ambrosini. “The company is going through a rapid period of development and transformation, and I look forward to working with the team to help drive its success. Having worked extensively in the healthcare sector, I am passionate about the impact companies such as Percheron can make in the lives of patients.”

With Ms Ambrosini’s appointment, Mr Phillip Hains, Partner at Acclime Group, will step down as CFO and Company Secretary. The company will continue to work closely with the Acclime Group team on its accounting and statutory compliance obligations.

“I want to thank Phillip Hains for his many years of support to the company,” added Dr Garner. “He and the team at, initially, CFO Solutions and, more recently, Acclime Group

have made an enormous contribution to the company, such that it has now matured to the stage where an in-house role makes sense.”

~ ENDS ~

---

### **About Percheron Therapeutics Limited**

Percheron Therapeutics Limited [ASX: PER | US OTC: ATHJY | FSE: AWY] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases. The company’s lead program is ATL1102, an antisense oligonucleotide targeting the CD49d receptor. ATL1102 is currently the subject of an ongoing international phase IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy (DMD), for which data is expected in 2H CY2024. The company previously reported promising results from an exploratory phase IIa study of in the same population and has been awarded orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA.

For more information, please contact [info@PercheronTx.com](mailto:info@PercheronTx.com).

*This announcement has been authorized for release to the Australian Securities Exchange  
by the Board of Directors.*

---